Background: RAD001 inhibits mTOR and is the standard treatment after failure of anti-VEGF-targeted therapies in patients with metastatic renal cell carcinoma (mRCC). We analyzed the course of disease ...

Nearly two-thirds of kidney cancer patients taking Novartis AG's RAD001 had progression of their disease delayed by a year, a significantly better result than in those taking placebo ...

Purpose Evaluate the activity of everolimus (RAD001) in combination with octreotide long-acting repeatable (LAR) in patients with advanced low- to intermediate-grade neuroendocrine tumors. Methods ...